Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the …
D Goldberg, IC Ditah, K Saeian, M Lalehzari… - Gastroenterology, 2017 - Elsevier
Background & Aims Concurrent to development of more effective drugs for treatment of
hepatitis C virus (HCV) infection, there has been an increase in the incidence of …
hepatitis C virus (HCV) infection, there has been an increase in the incidence of …
Systematic review: development of a consensus code set to identify cirrhosis in electronic health records
JE Shearer, JJ Gonzalez, T Min… - Alimentary …, 2022 - Wiley Online Library
Summary Background Electronic health records (EHRs) collate longitudinal data that can be
used to facilitate large‐scale research in patients with cirrhosis. However, there is no …
used to facilitate large‐scale research in patients with cirrhosis. However, there is no …
[PDF][PDF] Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement
Background and Aims Electronic health record (EHR)‐based research allows the capture of
large amounts of data, which is necessary in NAFLD, where the risk of clinical liver …
large amounts of data, which is necessary in NAFLD, where the risk of clinical liver …
[PDF][PDF] Risk prediction models for post‐operative mortality in patients with cirrhosis
Background and Aims Patients with cirrhosis are at increased risk of postoperative mortality.
Currently available tools to predict postoperative risk are suboptimally calibrated and do not …
Currently available tools to predict postoperative risk are suboptimally calibrated and do not …
Core concepts in pharmacoepidemiology: validation of health outcomes of interest within real‐world healthcare databases
EJ Weinstein, ME Ritchey… - … and drug safety, 2023 - Wiley Online Library
Real‐world healthcare data, including administrative and electronic medical record
databases, provide a rich source of data for the conduct of pharmacoepidemiologic studies …
databases, provide a rich source of data for the conduct of pharmacoepidemiologic studies …
[PDF][PDF] Incidence and mortality of acute‐on‐chronic liver failure using two definitions in patients with compensated cirrhosis
The term acute‐on‐chronic liver failure (ACLF) is intended to identify patients with chronic
liver disease who develop rapid deterioration of liver function and high short‐term mortality …
liver disease who develop rapid deterioration of liver function and high short‐term mortality …
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C Virus–monoinfected patients: a cohort …
Background: The incidence and determinants of hepatic decompensation have been
incompletely examined among patients co-infected with HIV and hepatitis C virus (HCV) in …
incompletely examined among patients co-infected with HIV and hepatitis C virus (HCV) in …
Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C–related compensated cirrhosis
Background & Aims Statins decrease portal pressure in patients with cirrhosis and increase
survival times of patients who have bled from varices. However, statins can be hepatotoxic. It …
survival times of patients who have bled from varices. However, statins can be hepatotoxic. It …
The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a veterans affairs cohort study
Background & Aims The impact of proton pump inhibitory (PPI) medications on adverse
outcomes in cirrhosis remains controversial. We aimed to evaluate the association between …
outcomes in cirrhosis remains controversial. We aimed to evaluate the association between …
Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events
Background & Aims Infection with hepatitis virus C (HCV) is associated with an increased
risk of cardiovascular disease (CVD) events. It is not clear whether treatment with direct …
risk of cardiovascular disease (CVD) events. It is not clear whether treatment with direct …